+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for treating pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor positive ERhuman epidermal growth factor 2 negative HER2- breast cancer that has an ESR1 mutation. This study focuses on patients who have previously received ribociclib or palbociclib-based treatment and aims to compare the effectiveness, safety, and tolerability of these two treatment combinations. Participants will receive either 5 mg per day of oral lasofoxifene plus oral abemaciclib 150 mg twice daily, or fulvestrant 500 mg given intramuscularly on Days 1, 15, and 29, then once monthly thereafter, combined with oral abemaciclib 150 mg twice daily. The study is randomized and open-label, allowing comparison between these two treatment combinations over time. During the study, participants will be closely monitored for progression-free survival, objective response rate, overall survival, clinical benefit rate, duration and time to response, time to cytotoxic chemotherapy, quality of life using a specific breast cancer assessment tool, and the incidence of adverse events. The study includes various assessments and safety monitoring over approximately three years to evaluate these outcomes and the participants response to the treatments.

Age: 18Years +All GendersPhase 3
224 locations
F

Actively Recruiting

Researchers are evaluating the safety and effectiveness of osimertinib tablets combined with Datopotamab Deruxtecan intravenous infusion compared to osimertinib alone as a first treatment for participants with locally advanced or metastatic non-small cell lung cancer NSCLC that has specific EGFR mutations Ex19del andor L858R. This global Phase III, open-label, randomized study includes participants who have not received prior therapy for advanced disease, aiming to assess treatment benefits over approximately 8 years. Participants are randomly assigned to one of two groups one group receives osimertinib 80 mg orally once daily plus Datopotamab Deruxtecan 6 mgkg by intravenous infusion every 3 weeks, while the other group receives osimertinib 80 mg orally once daily alone. Treatment continues until disease progression, unacceptable side effects, or other discontinuation reasons. Visits occur every 3 weeks during treatment, with additional assessments every 6 weeks from cycle 7 to cycle 17, then every 12 weeks for those on osimertinib alone or after discontinuing Datopotamab Deruxtecan. Participants will attend regular visits for treatment administration and assessments, including scans and laboratory tests to monitor disease status and safety. Researchers will measure progression-free survival, overall survival, response rates, and the impact on brain metastases over the study period. Pharmacokinetics and immunogenicity of the drugs will also be evaluated. The study includes continuous safety monitoring and may last up to 8 years, with visits and evaluations scheduled throughout treatment and follow-up.

Age: 18Years +All GendersPhase 3
167 locations
E

Actively Recruiting

Researchers are evaluating Datopotamab Deruxtecan Dato-DXd alone and combined with other anticancer drugs in patients with advanced or metastatic solid tumors. This Phase II, open-label, multicenter study uses a modular master protocol to assess safety, tolerability, recommended dosing, and effectiveness across several cancer types including endometrial, gastric, prostate, ovarian, colorectal, urothelial, and biliary tract cancers. The study allows simultaneous evaluation of Dato-DXd in various treatment combinations and disease settings. Participants receive Dato-DXd intravenously as monotherapy or combined with approved or novel anticancer agents, varying by cancer subtype. Treatment combinations include capecitabine, 5-Fluorouracil, prednisoneprednisolone, carboplatin, bevacizumab, volrustomig, rilvegostomig, and cisplatin. Each substudy tests either monotherapy or combination therapy tailored to the tumor type. The study follows participants during treatment and a safety follow-up period, with some treatments administered orally or intravenously depending on the agent. Throughout the approximately one-year study period, participants undergo regular assessments including tumor measurement, adverse event monitoring, pharmacokinetic sampling, and specific biomarker evaluations such as PSA, CA-125, and radiographic progression depending on cancer type. Researchers evaluate outcomes like objective response rate, progression-free survival, disease control, and overall survival. Safety is monitored closely during and up to 28 or 90 days after treatment discontinuation. Participants provide tumor samples for tissue analysis and may consent to optional genetic research.

Age: 18Years - 130YearsAll GendersPhase 2
96 locations